From new leadership to product launches, here are five key updates from spine and orthopedic devicemakers since Jan. 15.

Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of ...

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

This fall, pharmaceutical and medical technology company Johnson & Johnson announced that a newly created Dallas subsidiary ...

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

whole-body ultrasound today announced preliminary findings from a seminal study conducted by Rutgers Robert Wood Johnson Medical School (RWJMS) and Robert Wood Johnson University Hospital (RWJUH ...

The deal would help accelerate growth in J&J's drugs business after the company spun off its consumer health unit in 2023.

In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Hold rating on Johnson & Johnson (JNJ – Research Report), with ...

More powerful winds were expected to trigger new wildfires that could set back the recent progress made in containing blazes that have destroyed thousands of homes and killed at least 24 people ...

Other medical experts interviewed questioned ... evidence for health and for establishing a clean food supply chain," Johnson says. "And so we're hoping to bridge these things to the new ...

More powerful winds were expected to trigger new wildfires that could set back the recent progress made in containing blazes ...

The wind chill reached minus 27 and a fan nearly lost his fingers on a frigid night a year ago in Kansas City.